Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > PDC deal

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Nov 02, 2022 12:44am

99 Views

Post# 35065257

RE:RE:RE:PDC deal

One thing I wonder is just how much they are sparing healthy cells with this tech.
Here's a pretty comprehensive article about their payload which suggests it doesn't have the worst toxicity profile on it's own. So proving this tech is adding something new to the payload should be a big part of this but I wouldn't expect they'd be able to show this in Ph1. (But what do I know)

https://eknygos.lsmuni.lt/springer/557/317-341.pdf

(Maybe the buyer is just infected with greed. A cancer/target agnostic Erhurtu, sounds amazing)

qwerty22 wrote:

I always tend to think that Complete Responses are hard to ignore in these late-stage patients so getting one early must help a lot. The technology is great, potentially it's cancer type, genetic mutation, cancer target agnostic given that it uses a biophysical feature of many (most?) tumours. You can imagine an almost infinite solid tumour cancer market once you've proved the big questions. It's interesting they are happy to pay the big cash after proving a few more things in Ph1 tends to make you think they are less interested in seeing one particular indication proven out and will take a risk on just some serious PoC data.

Could get into super-speculative, hopium mode and say this drug might benefit from working with a drug that reinforces the anoxic conditions of a tumour. Say something that inhibits vascular formation :)

palinc2000 wrote:

Your take on the science ...Lots of$$ for a delivery system still in Phase1

palinc2000 wrote:

Qwerty
your take on this
https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-cybrexa-therapeutics-establish-exclusive